LONDON – Novo Holdings has inspired the formation of the second new fund in 18 months aiming to feed more capital into the commercialization of Scandinavian science, acting as cornerstone investor in Sound Bioventures Fund I. The new fund greeted the New Year with a first close of €110 million (US$124 million), to be invested in private biopharmas with late preclinical or clinical programs, primarily in rare diseases. Read More
Sihuan Pharmaceutical Holdings Group Ltd.’s subsidiary Xuanzhu Biopharmaceutical Co. Ltd. has raised ¥610.5 million ($96 million) in a series B round led by Sunshine Life Insurance Corp. Ltd. Read More
Sirnaomics Ltd. became the first RNA therapeutics company to list on the Hong Kong Stock Exchange (HKEX) with a $64 million initial public offering. Its shares (HKEX:2277) have since surged, rising to HK$93.90 ($12.04) on Jan. 4 following their debut at HK$65.90 per share. Read More
Avrobio Inc., stung by variable outcomes in a phase II test of its investigational Fabry disease therapy, is quitting further enrollment in the program, one of the first from its gene therapy platform, Plato. The team's attention will shift instead to other clinical-stage lysosomal disorder programs amid "an increasingly challenging market and regulatory environment for Fabry disease," the company said. Read More
After discussions with the FDA, Applied Therapeutics Inc. said it will again delay an NDA filing for its galactosemia treatment, AT-007, until it has more time to discuss the filing with the agency. Read More
LONDON - Synaffix BV’s third-generation linker and payloads have attracted therapeutic antibody veteran Genmab A/S in a potential S415 million licensing deal. Read More
Recent word that Johnson & Johnson submitted the BLA for teclistamab may have reminded Wall Street that a combo-therapy face-off is in progress between the big pharma firm – with partner Springworks Therapeutics Inc. – and Novartis AG, paired with Ayala Therapeutics Inc. Read More
A split decision from the U.S. Court of Appeals for the Federal Circuit could give Novartis AG’s blockbuster multiple sclerosis drug, Gilenya (fingolimod), a little more breathing room from unlicensed generics. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alentis, Alladapt, Asieris, Beigene, Celltrion, Compass, Dystrogen, Ensysce, Equillium, Gannex, Gritstone, Harbour, Mindmed, Relay, Vaccinex. Read More
